Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenues (Details Narrative)

Revenues (Details Narrative)	6 Months Ended
Revenues (Details Narrative)	Feb. 28, 2022 USD ($)
Estimates and Judgments
Product revenues	$ 17,500
licensing usage	$ 16,000